MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Milei Threatens Falkland Oil Firms With Sanctions 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
OpenAI Rejects Apple Trade Secret Theft Claims 
France Targets Shein, Temu With Fast-Fashion Fees 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Xiaomi Shares Jump on Europe EV Expansion Plan 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Add as a preferred source on Google
| Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) | ||
| Filing of the 2017 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report PARIS, France - March 7, 2018 - Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its "Document de Référence" containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). These documents are available on the "Investors" section of the company's corporate website (www.sanofi.com/en/investors/reports-and-publications). In addition, the Form 20-F is available on the website of the SEC (www.sec.gov) and the "Document de Référence" is available on the website of the AMF (www.amf-france.org). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request. | ||
| About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life | ||
| Media Relations Contact Laurence Bollack Tel.: +33 (0)1 53 77 46 46 [email protected] | Investor Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected] | |
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/6f36ccb1-cf99-4848-ab29-73e758e88168
